Last updated: August 7, 2026
Myrbetriq Granules is the pediatric formulation of mirabegron, an extended-release beta-3 adrenergic agonist marketed by Astellas Pharma for neurogenic detrusor overactivity in children. Its commercial opportunity is structurally different from the much larger adult overactive-bladder tablet market: the addressable population is smaller, diagnosis is concentrated in specialist care, treatment depends on weight-based dosing, and the granule formulation has greater manufacturing and substitution barriers.
Astellas does not report Myrbetriq Granules revenue separately. Financial performance is therefore assessed through the broader Myrbetriq, Betmiga and related mirabegron franchise, together with the pediatric product’s regulatory position, reimbursement profile and generic-launch risk.
What is Myrbetriq Granules and which patients use it?
Myrbetriq Granules is mirabegron formulated as an extended-release oral suspension. It is intended for pediatric patients aged 3 years and older with neurogenic detrusor overactivity, a bladder dysfunction commonly associated with spina bifida and other neurologic conditions.
The product is differentiated from Myrbetriq extended-release tablets in four ways:
| Attribute |
Myrbetriq Granules |
Myrbetriq tablets |
| Active ingredient |
Mirabegron |
Mirabegron |
| Dosage form |
Extended-release oral suspension |
Extended-release tablet |
| Core population |
Pediatric patients with neurogenic detrusor overactivity |
Primarily adults with overactive bladder; also adult neurogenic detrusor overactivity |
| Dosing |
Weight-based pediatric dosing |
Fixed-strength dosing |
| Distribution |
Pediatric urology, neurology and specialty pharmacy channels |
Retail, mail and specialty pharmacy channels |
| Substitution risk |
Lower because of formulation and dosing complexity |
Higher as tablet generics enter |
The FDA-approved pediatric dosing approach is based on body weight and requires preparation of the suspension from granules before administration. That creates a product-use barrier compared with standard tablets but also adds dispensing, education and handling requirements.[1]
What is the FDA regulatory status of Myrbetriq Granules?
The FDA approved Myrbetriq Granules under NDA 210357 for pediatric neurogenic detrusor overactivity. The product expanded mirabegron into a population in which oral liquid administration is clinically important because many children cannot reliably swallow tablets.
FDA regulatory milestones
| Milestone |
Product or franchise |
Regulatory significance |
| 2012 |
Myrbetriq extended-release tablets |
Initial U.S. approval for adult overactive bladder |
| 2018 |
Expanded adult indication |
Approval for adult neurogenic detrusor overactivity |
| 2021 |
Myrbetriq Granules |
Pediatric formulation approval for neurogenic detrusor overactivity |
| Post-approval period |
Pediatric labeling and distribution |
Commercial use in specialist pediatric populations |
The granules approval is a formulation and population expansion rather than a new active pharmaceutical ingredient. This distinction limits the likelihood of a long, standalone exclusivity period comparable to a first-in-class product.
What patents protect Myrbetriq Granules?
Myrbetriq Granules is protected through a combination of formulation, dosing, method-of-use and product-specific regulatory rights. The commercially relevant estate is broader than any single patent because different rights may cover:
- Mirabegron composition and pharmaceutical use.
- Extended-release delivery.
- Granule or oral-suspension formulation.
- Pediatric dosing based on body weight.
- Treatment of neurogenic detrusor overactivity.
- FDA-listed patents associated with the approved product and its labeling.
The core composition and early formulation patents are older than the pediatric granules approval. As a result, the granules product’s defensibility depends more heavily on later formulation and use claims than on basic compound protection.
Orange Book position
The FDA Orange Book is the controlling source for patents listed against the relevant U.S. product and NDA. Patent listings can differ between Myrbetriq tablets and Myrbetriq Granules because the products have different dosage forms, approved uses and regulatory applications.[2]
A practical patent review should separate:
- Patents listed against the tablet NDA.
- Patents listed against the granules NDA.
- Pediatric-use patents.
- Formulation patents covering the extended-release suspension.
- Regulatory exclusivity associated with the pediatric indication.
- Any patent-term extensions or pediatric exclusivity attached to earlier rights.
The granules product should not be treated as having the same loss-of-exclusivity date as the tablets. A generic tablet launch can occur without creating an interchangeable substitute for the pediatric suspension.
When does Myrbetriq Granules lose exclusivity?
Myrbetriq Granules does not have one definitive commercial loss-of-exclusivity date. Market entry depends on the expiry or invalidation of multiple rights and on whether an applicant develops an equivalent pediatric extended-release suspension.
The relevant timeline is:
| Protection category |
Commercial effect |
| Active-ingredient patents |
May restrict mirabegron products broadly but are generally the oldest rights |
| Extended-release formulation patents |
Can delay equivalent-release products |
| Pediatric method-of-use patents |
May limit labeled pediatric competition |
| Granule or suspension patents |
Potentially the most relevant rights for direct granules competition |
| FDA exclusivity |
Can delay approval even after patent issues are resolved |
| Pediatric exclusivity |
May add six months to qualifying patent or regulatory protection |
For investors and licensing teams, the key issue is not simply the first date on which a mirabegron tablet generic can launch. The more relevant date is when a competitor can legally and commercially sell a pharmaceutically equivalent pediatric oral suspension with an FDA-approved label.
Are there Paragraph IV challenges to Myrbetriq Granules?
Paragraph IV risk is materially higher for Myrbetriq tablets than for Myrbetriq Granules. Generic applicants typically target the largest volume opportunity first, and adult tablets have a much larger prescription base than pediatric suspension.
A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. If the reference sponsor files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to litigation outcomes and applicable regulatory events.[3]
Competitive implications
| Challenge target |
Expected commercial incentive |
Likely impact |
| Adult 25 mg and 50 mg tablets |
High |
Direct erosion of adult franchise revenue |
| Pediatric granules |
Lower |
Limited volume but potentially high-value specialty pricing |
| Alternative pediatric formulations |
Moderate |
May compete without being an exact generic substitute |
| Off-label tablet use in children |
Limited by swallowing and dosing constraints |
Clinical substitution risk varies by patient |
Publicly disclosed litigation involving mirabegron has primarily centered on adult tablet patents and generic applicants. A tablet Paragraph IV settlement does not automatically authorize a generic granule product. The legal analysis must examine the asserted claims, the dosage form, the approved indication and any carve-out language.
What formulation patents protect the granule product?
The formulation is commercially important because mirabegron is delivered through an extended-release system, while the patient receives it as a prepared suspension. A competing manufacturer must reproduce several technical characteristics:
- Consistent drug dispersion in the suspension.
- Controlled release over the intended dosing interval.
- Stability after reconstitution.
- Acceptable taste and pediatric tolerability.
- Accurate administration across weight-based doses.
- Compatibility with the supplied measuring device.
- Microbiological and storage stability after preparation.
These requirements create manufacturing and regulatory barriers beyond ordinary immediate-release oral liquids. An ANDA applicant would need to demonstrate pharmaceutical equivalence and bioequivalence or satisfy an alternative FDA pathway accepted for the product. A formulation that is clinically usable but not pharmaceutically equivalent may require a separate NDA or a different regulatory strategy.
Manufacturing barriers
Myrbetriq Granules requires specialized control over particle characteristics, coating or matrix technology, reconstitution behavior and dose uniformity. Small pediatric volumes increase the importance of accurate filling and packaging. The product also requires supply-chain controls for granules, diluent or reconstitution materials, labeling and administration devices.
These factors reduce the attractiveness of a low-volume generic launch. They also increase the value of any patent claims that cover the release profile, granule architecture, suspension stability or reconstitution process.
How strong is the Myrbetriq Granules patent estate?
The estate is stronger commercially than a simple compound-patent analysis suggests, but weaker than the estate of a new chemical entity with long-lived composition claims.
Strengths
- Pediatric neurogenic detrusor overactivity is a specialized indication.
- The oral suspension format addresses a clear administration need.
- Weight-based dosing complicates direct tablet substitution.
- Formulation equivalence may require specialized manufacturing.
- The product can retain clinical utility after adult tablet patents are challenged.
Weaknesses
- The active ingredient is established and widely characterized.
- The pediatric market is relatively small.
- A limited number of specialist prescribers may facilitate competitor education.
- Adult tablet generics can reduce brand infrastructure and payer support.
- Some patients may transition to other antimuscarinic or device-based therapies.
- Patent expiry for earlier mirabegron rights limits the ability to sustain broad molecule-level exclusivity.
Overall, the granules product has a targeted defensive position rather than a broad franchise-wide monopoly. Its most durable protection is likely to arise from product-specific formulation and pediatric-use rights, combined with manufacturing complexity.
What is the market size for Myrbetriq Granules?
The addressable market is a subset of pediatric patients with neurogenic bladder, particularly children with spina bifida and related neurologic disorders. It is substantially smaller than the adult overactive-bladder market.
The commercial model has several characteristics:
- Low patient volume relative to adult oral bladder drugs.
- High clinical concentration in pediatric urology centers.
- Greater dependence on prior authorization and specialty pharmacy.
- Higher medication-management costs.
- Lower probability of rapid mass-market generic substitution.
- Greater sensitivity to institutional formulary decisions.
The product can command a higher net price per patient than a conventional generic tablet because it solves a formulation and administration problem. That pricing advantage is offset by the small patient population and the cost of specialist promotion.
What is the financial trajectory of the Myrbetriq franchise?
Astellas reports mirabegron revenue at the franchise level, generally including Myrbetriq, Betmiga and regional brands. It does not separately disclose Myrbetriq Granules sales. The pediatric product is therefore a revenue-protection and lifecycle-management asset, not an independently visible financial segment.
Revenue trajectory
| Period |
Financial direction |
Main driver |
| Early launch period |
Incremental growth |
Entry into pediatric neurogenic detrusor overactivity |
| Franchise maturity |
Stable-to-declining |
Adult market saturation and patent pressure |
| Generic tablet-entry period |
Downward pressure |
Price and volume erosion in adult tablets |
| Granules post-tablet erosion |
More resilient niche revenue |
Limited direct substitution and specialist demand |
The granules product is unlikely to offset large-scale erosion of adult tablet revenue on its own. Its strategic value is in extending the life of the mirabegron franchise, preserving prescriber relationships and retaining patients who need a liquid dosage form.
Astellas’ broader financial exposure to Myrbetriq is meaningful because the drug has been one of the company’s major established products. Company filings have reported mirabegron revenue in the hundreds of billions of yen annually at the global franchise level, but those figures include multiple dosage forms and territories.[4] Granules revenue is not separately itemized.
What generic launch scenarios exist for Myrbetriq Granules?
Scenario 1: Adult tablet generics launch first
This is the most likely sequencing. Generic tablets reduce franchise revenue while Myrbetriq Granules remains protected or commercially insulated. Astellas may preserve pediatric pricing and specialist access even as adult volume shifts to generics.
Scenario 2: An authorized or licensed pediatric competitor enters
A licensing arrangement or authorized-generic strategy could provide a competitor with formulation, manufacturing or distribution capabilities. This would accelerate price competition while reducing the technical burden of independent development.
Scenario 3: Direct generic granules entry
A direct competitor would need an equivalent extended-release suspension, appropriate pediatric labeling and a viable reimbursement strategy. This scenario presents the greatest erosion risk to the granules product but is less attractive than tablet entry because of the smaller market.
Scenario 4: Therapeutic substitution
Competitors may use oxybutynin, other antimuscarinics, catheterization programs or alternative bladder-management approaches. These products do not necessarily require pharmaceutical equivalence but can limit market expansion.
Which companies compete with Myrbetriq Granules?
Competition falls into three groups:
| Competitive group |
Examples |
Competitive mechanism |
| Mirabegron generics |
Generic tablet manufacturers |
Lower-cost adult and potentially selected pediatric use |
| Antimuscarinic drugs |
Oxybutynin and related products |
Established treatment alternatives for neurogenic bladder |
| Non-drug management |
Intermittent catheterization and specialist bladder programs |
Clinical substitution or combination treatment |
Large generic manufacturers with existing mirabegron tablet capabilities have the strongest platform for evaluating a pediatric formulation. However, tablet approval does not establish technical equivalence to Myrbetriq Granules.
What licensing deals affect Myrbetriq Granules?
No major publicly disclosed licensing transaction has established a separate commercial market for Myrbetriq Granules. Astellas retains control of the core product franchise in major markets, while regional commercialization arrangements for mirabegron may vary by jurisdiction.
Potential transaction value would depend on:
- Rights to pediatric indications.
- Access to the granule manufacturing process.
- Geographic scope.
- Ownership of formulation patents.
- Regulatory status in the United States, Europe and Japan.
- Responsibility for specialty distribution and pharmacovigilance.
The granules product is more likely to be included in a broader mirabegron regional deal than transferred as an isolated asset.
What patent litigation affects the Myrbetriq franchise?
Litigation risk is concentrated in the adult tablet market, where generic applicants have the largest economic incentive. Key litigation questions include:
- Whether listed patents cover the generic’s formulation or only specific uses.
- Whether a generic can launch with a label that omits protected pediatric indications.
- Whether a settlement permits an early date for adult tablet entry.
- Whether patent claims covering extended release also reach the oral suspension.
- Whether a court decision invalidating a tablet patent affects granules claims.
A settlement that permits tablet entry before the end of all listed patent terms can materially reduce Astellas’ revenue while leaving granules commercially protected. Patent litigation should therefore be modeled by dosage form, indication and market segment rather than by the Myrbetriq brand name alone.
How does Myrbetriq Granules compare with other pediatric bladder medicines?
Myrbetriq Granules has a different positioning from older antimuscarinic therapies.
| Factor |
Myrbetriq Granules |
Antimuscarinic oral liquids |
| Pharmacology |
Beta-3 adrenergic agonist |
Muscarinic receptor blockade |
| Main use in this context |
Pediatric neurogenic detrusor overactivity |
Neurogenic bladder and related conditions |
| Administration |
Reconstituted extended-release suspension |
Often immediate-release liquid or tablet |
| Differentiation |
Avoids some anticholinergic burden |
Established clinical familiarity and lower cost |
| Generic risk |
Lower direct risk in specialized granule format |
Often higher because older products have generic competition |
| Commercial limitation |
Small pediatric population and pricing scrutiny |
Tolerability and adherence limitations |
The product’s commercial opportunity depends on patients for whom beta-3 agonist therapy is clinically preferred, poorly served by antimuscarinics, or easier to administer than tablets.
Key Takeaways
- Myrbetriq Granules is a pediatric mirabegron suspension for neurogenic detrusor overactivity, not a mass-market extension of the adult tablet business.
- Astellas does not disclose separate granules revenue, so financial analysis must use franchise-level mirabegron data.
- Adult tablet generics pose the primary near-term revenue risk to the Myrbetriq franchise.
- Direct generic competition to granules is more difficult because of extended-release suspension technology, pediatric dosing and manufacturing requirements.
- The strongest commercial protection is likely to come from formulation, pediatric-use and regulatory rights rather than from broad compound exclusivity.
- A tablet Paragraph IV settlement or launch does not automatically establish a legal pathway for a pediatric granules competitor.
- The product’s value is primarily lifecycle management: it preserves a specialist pediatric niche after adult tablet erosion begins.
FAQs About Myrbetriq Granules
Is Myrbetriq Granules interchangeable with Myrbetriq tablets?
No. The products have different dosage forms, dosing instructions and approved patient populations. Tablet substitution should not be assumed to provide equivalent release or pediatric dosing.
Can a generic mirabegron tablet be used for pediatric neurogenic detrusor overactivity?
A physician may prescribe a product based on clinical judgment, but a generic tablet is not automatically an FDA-equivalent substitute for Myrbetriq Granules.
Does adult mirabegron patent expiry eliminate protection for Myrbetriq Granules?
No. Granules may have separate formulation, pediatric-use and regulatory protections.
Is Myrbetriq Granules a biologic or biosimilar product?
No. Mirabegron is a small-molecule drug. Competitors would generally pursue an abbreviated new drug application or another applicable small-molecule pathway, not a biosimilar application.
What is the main investment risk for Myrbetriq Granules?
The main risk is indirect erosion from adult tablet generics and therapeutic substitution, followed by direct competition from a technically capable generic manufacturer that develops an equivalent pediatric extended-release suspension.
References
- U.S. Food and Drug Administration. (2021). Myrbetriq Granules prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards guidance for industry.
- Astellas Pharma Inc. (2024). Annual report and consolidated financial results.
